Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05373615 · ClinicalTrials.gov registry record · Phase 1
Cefiderocol Plasma Concentrations in Patients Receiving Renal Replacement Therapy
A Phase 1 study, sponsored by Hartford Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT05373615 is a Phase 1 study that has completed, run by Hartford Hospital. The registered enrollment target is 14 participants.
The verdict
NCT05373615, a Phase 1 study, has completed, sponsored by Hartford Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
Continuous renal replacement therapies (CRRT) such as continuous venovenous hemofiltration are used to provide renal support for critically ill patients with acute kidney injury (AKI), particularly patients who are hemodynamically unstable. It is well known that critically ill patients may experience alterations in antibiotic pharmacokinetics, and as a result, dosing modifications are generally required. There is a need to understand how CRRT affect the pharmacokinetics and disposition of drugs. This study is designed to assess the pharmacokinetics of the new broad-spectrum antibiotic, Cefiderocol, in critically ill patient receiving CRRT.
Interventions
- DRUG Cefiderocol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2022-07-25 |
| Est. Completion | 2024-11-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05373615
The ClinicalTrials.gov registry entry for NCT05373615 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hartford Hospital, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cefiderocol is the first listed.
NCT05373615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05373615 about?
NCT05373615 is a clinical study titled "Cefiderocol Plasma Concentrations in Patients Receiving Renal Replacement Therapy". Continuous renal replacement therapies (CRRT) such as continuous venovenous hemofiltration are used to provide renal support for critically ill patients with acute kidney injury (AKI), particularly patients who are hemodynamically unstable. It is well known that critically ill patients may experienc...
What is the current status of trial NCT05373615?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2022-07-25. Estimated completion is 2024-11-20.
What interventions are being tested in trial NCT05373615?
The interventions under investigation include: Cefiderocol (DRUG).
Who is sponsoring clinical trial NCT05373615?
This trial is sponsored by Hartford Hospital, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.